Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1984 Jan;49(1):33–42. doi: 10.1038/bjc.1984.6

Sensitization of normal and malignant tissue to cyclophosphamide by nitroimidazoles with different partition coefficients.

D G Hirst, J L Hazlehurst, J M Brown
PMCID: PMC1976681  PMID: 6229264

Abstract

The ability of a range of 2-nitroimidazoles with similar electron affinities but widely differing partition coefficients (P) to enhance the cytotoxicity of cyclophosphamide (CY) in mouse tumour and normal tissues was investigated. In a preliminary study large single doses of benznidazole (BENZ), misonidazole (MISO), desmethylmisonidazole (DMM), and SR-2508 were found to give similar enhancement of the RIF-1 and SCC VII/St tumours. SR-2555 was less effective. A direct comparison was made between MISO and SR-2508 using prolonged, low-level drug exposures, achieved by multiple injections. The enhancement of CY cytotoxicity achieved in the two tumour systems (RIF-1 and SCC VII/St) was found to be similar for a given blood sensitizer concentration. In the normal tissue assays (white blood cell count, bone marrow CFU-S and testis spermatogonia) neither MISO nor SR-2508 produced significant enhancement of CY cytotoxicity, so that the therapeutic gains achieved at a given blood concentration of sensitizer were similar for SR-2508 and MISO. The main advantage of SR-2508, however, will probably lie in its lower toxicity, permitting higher blood levels to be achieved. However, the slope of the dose response curves are rather shallow so we would not predict a dramatically increased benefit.

Full text

PDF
33

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brown D. M., Gonzalez-Mendez R., Brown J. M. Factors influencing intracellular uptake and radiosensitization by 2-nitroimidazoles in vitro. Radiat Res. 1983 Mar;93(3):492–505. [PubMed] [Google Scholar]
  2. Brown J. M., Hirst D. G. Effect of clinical levels of misonidazole on the response of tumour and normal tissues in the mouse to alkylating agents. Br J Cancer. 1982 May;45(5):700–708. doi: 10.1038/bjc.1982.111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Brown J. M., Twentyman P. R., Zamvil S. S. Response to the RIF-1 tumor in vitro and in C3H/Km mice to X-radiation (cell survival, regrowth delay, and tumor control), chemotherapeutic agents, and activated macrophages. J Natl Cancer Inst. 1980 Mar;64(3):605–611. [PubMed] [Google Scholar]
  4. Conroy P. J., McNeill T. H., Passalacqua W., Merritt J., Reich K. R., Walker S. Nitroimidazole neurotoxicity: are mouse studies predictive? Int J Radiat Oncol Biol Phys. 1982 Mar-Apr;8(3-4):799–803. [PubMed] [Google Scholar]
  5. Hinchliffe M., McNally N. J., Stratford M. R. The effect of radiosensitizers on the pharmacokinetics of melphalan and cyclophosphamide in the mouse. Br J Cancer. 1983 Sep;48(3):375–383. doi: 10.1038/bjc.1983.202. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Hirst D. G., Brown J. M., Hazlehurst J. L. Enhancement of CCNU cytotoxicity by misonidazole: possible therapeutic gain. Br J Cancer. 1982 Jul;46(1):109–116. doi: 10.1038/bjc.1982.172. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Hirst D. G., Brown J. M. The therapeutic potential of misonidazole enhancement of alkylating agent cytotoxicity. Int J Radiat Oncol Biol Phys. 1982 Mar-Apr;8(3-4):639–642. doi: 10.1016/0360-3016(82)90702-7. [DOI] [PubMed] [Google Scholar]
  8. Law M. P., Hirst D. G., Brown J. M. Enhancing effect of misonidazole on the response of the RIF-1 tumour to cyclophosphamide. Br J Cancer. 1981 Aug;44(2):208–218. doi: 10.1038/bjc.1981.172. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Lee F. Y., Workman P. Modification of CCNU pharmacokinetics by misonidazole--a major mechanism of chemosensitization in mice. Br J Cancer. 1983 May;47(5):659–669. doi: 10.1038/bjc.1983.104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Lu C. C., Meistrich M. L. Cytotoxic effects of chemotherapeutic drugs on mouse testis cells. Cancer Res. 1979 Sep;39(9):3575–3582. [PubMed] [Google Scholar]
  11. McNally N. J., Hinchliffe M., de Ronde J. Enhancement of the action of alkylating agents by single high, or chronic low doses of misonidazole. Br J Cancer. 1983 Aug;48(2):271–278. doi: 10.1038/bjc.1983.182. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Siemann D. W. Response of murine tumours to combinations of CCNU with misonidazole and other radiation sensitizers. Br J Cancer. 1982 Feb;45(2):272–281. doi: 10.1038/bjc.1982.43. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. TILL J. E., McCULLOCH E. A. A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. Radiat Res. 1961 Feb;14:213–222. [PubMed] [Google Scholar]
  14. Taylor Y. C., Evans J. W., Brown J. M. Mechanism of sensitization of Chinese hamster ovary cells to melphalan by hypoxic treatment with misonidazole. Cancer Res. 1983 Jul;43(7):3175–3181. [PubMed] [Google Scholar]
  15. Twentyman P. R., Brown J. M., Gray J. W., Franko A. J., Scoles M. A., Kallman R. F. A new mouse tumor model system (RIF-1) for comparison of end-point studies. J Natl Cancer Inst. 1980 Mar;64(3):595–604. [PubMed] [Google Scholar]
  16. Urtasun R., Band P., Chapman J. D., Feldstein M. L., Mielke B., Fryer C. Radiation and high-dose metronidazole in supratentorial glioblastomas. N Engl J Med. 1976 Jun 17;294(25):1364–1367. doi: 10.1056/NEJM197606172942503. [DOI] [PubMed] [Google Scholar]
  17. Workman P., Brown J. M. Structure-pharmacokinetic relationships for misonidazole analogues in mice. Cancer Chemother Pharmacol. 1981;6(1):39–49. doi: 10.1007/BF00253009. [DOI] [PubMed] [Google Scholar]
  18. Workman P., Twentyman P. R. Enhancement by electron-affinic agents of the therapeutic effects of cytotoxic agents against the KHT tumor: structure-activity relationships. Int J Radiat Oncol Biol Phys. 1982 Mar-Apr;8(3-4):623–626. doi: 10.1016/0360-3016(82)90698-8. [DOI] [PubMed] [Google Scholar]
  19. Workman P., Twentyman P. R. Structure/activity relationships for the enhancement by electron-affinic drugs of the anti-tumour effect of CCNU. Br J Cancer. 1982 Aug;46(2):249–259. doi: 10.1038/bjc.1982.190. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES